FLHLFFilament Health Corp.

About Filament Health Corp. (FLHLF)

Filament Health Corp. (FLHLF) is a Drug Manufacturers - Specialty & Generic company headquartered in Burnaby, BC, Canada whose shares trade over-the-counter on the OTCQB tier.

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in house GMP facility, and Health Canada Dealers License for all natural psychedelics. Filament is headquartered in Vancouver, British Columbia.

Products and services

For pharmaceutical clinical trial candidates, Filament possesses the capabilities to manufacture in-house clinical drug candidates. In addition, Filament’s capabilities allow it to manufacture drug candidates for third parties wishing to pursue their own clinical development program. In these cases, Filament and the third parties will enter into intellectual property licensing agreements whereby Filament will potentially earn commercial milestones and royalty payments based upon future levels of commercialization met by the third party clinical development program. Filament’s first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: - PEX010 Psilocybin - oral delivery (1mg and 25mg) - PEX020 Psilocin - oral delivery (dose withheld) - PEX030 Psilocin - sublingual delivery (dose withheld) PEX010, PEX020 and PEX030 have successfully attained FDA Botanical Drug classification, a unique development pathway in comparison to isolated natural and synthetic compounds. As of March [31], 2022, Filament’s PEX010 drug candidate also obtained approval from Health Canada to be administered in clinical trials. Filament has also developed the following standardized drug candidates which are in preclinical stage: - AEX010 Ayahuasca - oral delivery (dose withheld) - AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld)

FLHLF key facts

Ticker symbol

FLHLF

Market tier

OTCQB

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Burnaby, BC, Canada

Country of incorporation

CA

Year of incorporation

2020

Employees

11

Estimated market cap

$5.03M (as of Apr 15, 2025)

Shares outstanding

261,793,970

Reporting standard

International Reporting: CBOE Canada

Audit status

Audited

Fiscal year end

12/31

Latest filing

Interim Financial Report (Sep 30, 2024)

Filament Health Corp. leadership

• Benjamin Theodore Lightburn — CEO, Co-Founder
• Lisa Frances Ranken — COO
• Steven Nguyen — Interim CFO
• Ryan Moss — Chief Scientific Officer

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with F